Metformin SR Tablet (DuLeNing) and Glucophage in Patients With Type 2 Diabetes

To perform a RCT for the comparison between Metformin hydrochloride sustained-release tablets made in Conquer pharmaceutical co., LTD and Glucophage .

Inclusion criteria

• Well informed of the procedures of this trial and informed consent is obtained
• Voluntarily accept standardized treatment 3.18-75 years old, gender is not limited

4.Newly diagnosed as type 2 diabetes and have not yet received any hypoglycemic therapy 5.Unable to control the blood glucose by diet and exercise: 7.5% ≤HbA1c ≤11.0%, in screening and before randomization 6.BMI: 19~35 kg/m2 7.Well compliance 8.Capable of self blood Glucose monitoring

Exclusion criteria

• Pregnant or lactating
• Type 1 diabetes
• Poor blood glucose control（HbA1c>11%）
• A history of malignant tumor
• Abnormal liver or renal function (defined as alanine aminotransferase(ALT)>2.5 times higher than normal range,or eGFR<45 mL/min per 1•73 m²)
• Poor blood pressure control [systolic blood pressure(SBP)>180mmHg,or diastolic blood pressure(DBP)>110mmHg]
• With severe heart disease,cardiac function worse than grade II,anemia(Hb<9.0g/d1)
• Continuous use of antidiabetic drugs more than one week in recent 3 months
• History of acute metabolic complications in recent 6 months
• Blood routine test indicates that the white blood cell count(WBC) <3*109/l
• Body Mass Index(BMI)<18.5 or ≥35kg/m2
• Drug or alcohol abuse
• Accompanying mental disorder who can't collaborate
• Abnormal digestion and absorption function
• Other endocrine diseases
• Other chronic diseases needed long-term glucocorticoid treatment
• With severe infection, immune dysfunction
• A history of metformin allergies or allergic constitution